COVID-19 drew unprecedented attention to the vagus nerve. As the primary conduit of the cholinergic anti-inflammatory pathway and the chief regulator of cardiorespiratory autonomic function, the vagus nerve sits at the intersection of nearly every system that SARS-CoV-2 disrupts. This article covers what we now know about how COVID-19 affects the vagus nerve, the vagus nerve’s role in the immune response to infection, and emerging therapeutic approaches targeting vagal pathways for both acute and long COVID.
The Cholinergic Anti-Inflammatory Pathway
The vagus nerve regulates inflammation through a mechanism identified by Kevin Tracey and colleagues called the cholinergic anti-inflammatory pathway. When vagal efferent fibres are activated, they release acetylcholine at the celiac ganglion, which in turn signals to the spleen via the splenic nerve. In the spleen, acetylcholine binds to alpha-7 nicotinic acetylcholine receptors on macrophages, suppressing the production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6.
This pathway is directly relevant to COVID-19 because the severe form of the disease is characterised by a cytokine storm, an excessive and dysregulated inflammatory response that causes acute respiratory distress syndrome (ARDS), multi-organ damage, and death. TNF-alpha and IL-6, two of the cytokines most consistently elevated in severe COVID-19, are precisely the cytokines that vagal activation suppresses. The question of whether augmenting vagal activity could dampen the cytokine storm became an active area of investigation from early in the pandemic.
How COVID-19 Damages the Vagus Nerve
SARS-CoV-2 can affect the vagus nerve through several mechanisms. The virus enters cells via the ACE2 receptor, which is expressed in multiple tissues innervated by the vagus nerve including the lungs, heart, and gastrointestinal tract. Inflammation in these tissues can damage vagal nerve endings and disrupt afferent signalling to the brainstem.
Post-mortem studies have identified SARS-CoV-2 viral proteins in the vagal ganglia and brainstem nuclei of deceased COVID-19 patients, suggesting that the virus can directly infect vagal neurons. The nodose ganglion, which contains the cell bodies of vagal afferent neurons, expresses ACE2 and is therefore a potential site of direct viral entry. Whether this represents productive viral replication or passive uptake of viral material remains under investigation.
A 2022 pilot study published in Clinical Microbiology and Infection examined 348 long COVID patients and found objective evidence of vagus nerve dysfunction in a significant proportion. Findings included vocal cord paresis (suggesting recurrent laryngeal nerve involvement), reduced diaphragmatic excursion (suggesting phrenic and vagal motor dysfunction), and abnormal cardiac autonomic testing. The authors proposed that vagus nerve dysfunction could be a central pathogenic mechanism underlying multiple long COVID symptoms.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Vagal Dysfunction in Long COVID
Long COVID, defined as persistent symptoms lasting more than 12 weeks after acute SARS-CoV-2 infection, affects an estimated 10 to 30 percent of people who contract COVID-19. Many of the hallmark symptoms of long COVID map onto vagal dysfunction: fatigue, brain fog, orthostatic intolerance (POTS), gastrointestinal dysmotility, tachycardia, voice changes, and difficulty swallowing.
Postural orthostatic tachycardia syndrome (POTS) has been one of the most studied manifestations of post-COVID dysautonomia. In POTS, the heart rate increases excessively upon standing, typically by 30 beats per minute or more. This can reflect reduced vagal tone (inadequate parasympathetic braking on heart rate), excessive sympathetic activation, or both. Tilt table testing in post-COVID POTS patients frequently shows patterns consistent with impaired vagal function.
Heart rate variability (HRV) studies in long COVID patients consistently show reduced vagal indices compared to recovered controls. Low RMSSD and reduced high-frequency HRV indicate diminished cardiac vagal modulation. These findings persist for months to years after acute infection in some individuals, suggesting that vagal damage may be slow to recover or, in some cases, permanent.
Gastrointestinal symptoms in long COVID, including early satiety, nausea, gastroparesis-like slowed gastric emptying, and altered bowel habits, are consistent with vagal motor and sensory dysfunction in the gut. The vagus nerve controls gastric motility, acid secretion, and pancreatic enzyme release. When vagal input to the GI tract is impaired, the coordinated processes of digestion break down.
Vagus Nerve Stimulation for COVID-19
Given the vagus nerve’s anti-inflammatory properties, several research groups have investigated vagus nerve stimulation as a therapeutic intervention for COVID-19. The rationale is straightforward: if the cytokine storm drives severe disease, and vagal activation suppresses pro-inflammatory cytokines, then stimulating the vagus nerve might reduce disease severity.
Transcutaneous auricular vagus nerve stimulation (taVNS) has been the primary modality studied, because it is non-invasive and can be rapidly deployed. Several pilot studies and small clinical trials examined taVNS in hospitalised COVID-19 patients. Results have been mixed. Some studies reported reductions in inflammatory markers and improvements in respiratory function, while others showed no significant benefit. The heterogeneity of patient populations, stimulation parameters, and timing of intervention makes it difficult to draw firm conclusions from the current evidence.
gammaCore, a non-invasive cervical VNS device already FDA-cleared for migraine and cluster headache, received Emergency Use Authorization for use in COVID-19 patients with respiratory distress. Early case series reported improvements in respiratory symptoms, but large-scale randomised data are limited.
For long COVID, taVNS is being actively investigated. Clinical trials registered in 2025 and 2026 are evaluating taVNS for long COVID fatigue, dysautonomia, and cognitive dysfunction. A feasibility study published in 2025 examined taVNS using a standard TENS device in women with long COVID fatigue and reported that the approach was well-tolerated and acceptable to patients, though efficacy data from controlled trials are still awaited.
What This Means for Recovery
For individuals recovering from COVID-19 with persistent autonomic symptoms, several evidence-based approaches may support vagal recovery. Regular moderate aerobic exercise, introduced gradually and adjusted for exercise intolerance, has the strongest evidence base for improving vagal tone over time. Slow-paced breathing at approximately 6 breaths per minute (resonance frequency breathing) can increase cardiac vagal modulation in individual sessions and, with regular practice, may produce lasting improvements.
Adequate hydration and salt intake are important for managing orthostatic symptoms in post-COVID dysautonomia. Compression garments can help maintain venous return. For POTS specifically, a structured exercise programme beginning with recumbent exercises (rowing, swimming, recumbent cycling) and gradually progressing to upright exercise has shown benefit in multiple studies.
Monitoring HRV with a wearable device can provide objective feedback on autonomic recovery over time. An upward trend in resting RMSSD or HF-HRV suggests improving vagal function, while persistently low values may warrant formal autonomic testing.
It is important to emphasise that long COVID is a medical condition that benefits from coordinated clinical care. Self-treatment with vagal stimulation techniques should complement, not replace, evaluation by a healthcare provider familiar with post-COVID syndromes. Dysautonomia clinics and long COVID specialty clinics have become increasingly available and can provide the structured diagnostic and therapeutic approach these patients need.
The vagus nerve’s role in immune regulation, autonomic function, and recovery from illness is one of the most active areas of medical research today. The My Vagus Nerve & Me eBook covers the science of vagal function and evidence-based approaches to supporting vagal health. Get My Vagus Nerve & Me eBook and understand how this critical nerve influences your body’s response to infection and recovery.
